Pancreatic Cancer Research

ResearcherNanjing University of Chinese MedicineActive in the last 2 years

Yudong Qiu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6017-9757; OpenAlex author ID A5065479590. Sources: OpenAlex.

Their work

Papers
18 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
48
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: 6 papers · 2023: none · 2024: 3 papers · 2025: 4 papers · 2026: 1 paper

Papers 18

  1. Prognostic value of neural invasion for resectable pancreatic ductal adenocarcinoma Co-author DOI 10.1016/j.asjsur.2026.03.074↗
  2. SP1-Mediated Glycolytic Reprogramming Promotes Tumorigenesis and Progression in Pancreatic Cancer. Co-author DOI 10.1002/advs.202510071↗
  3. Clinical characteristics of pancreatic cancer presenting with acute pancreatitis: a propensity-matched cohort study. Co-author DOI 10.1007/s00464-025-11654-z↗
  4. Survival and pathological response in pancreatic ductal adenocarcinoma after preoperative therapy with PD-1 blockade plus chemoradiotherapy followed by surgica… Co-author DOI 10.1080/07853890.2025.2541314↗
  5. DHCR7 Promotes Liver Metastasis of Pancreatic Cancer Through PI3K-Akt Signaling Pathway. Co-author DOI 10.1111/cas.70185↗
  6. DTX3L Accelerates Pancreatic cancer Progression via FAK/PI3K/AKT Axis. Last author DOI 10.1007/s10528-023-10451-4↗
  7. Loss of Claudin-1 incurred by DNMT aberration promotes pancreatic cancer progression. Co-author DOI 10.1016/j.canlet.2024.216611↗
  8. Comparison of prognosis and postoperative morbidities between standard pancreaticoduodenectomy and the TRIANGLE technique for resectable pancreatic ductal aden… Co-author DOI 10.4240/wjgs.v16.i3.689↗
  9. Pancreatic cancer-associated diabetes mellitus is characterized by reduced β-cell secretory capacity, rather than insulin resistance. Co-author DOI 10.1016/j.diabres.2022.109223↗
  10. Folate receptor-positive circulating tumor cells predict survival and recurrence patterns in patients undergoing resection for pancreatic cancer. Co-author DOI 10.3389/fonc.2022.1012609↗
  11. Therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in unresectable pancre… Co-author DOI 10.3389/fonc.2022.1015232↗
  12. Molecular Landscape and Prognostic Biomarker Analysis of Advanced Pancreatic Cancer and Predictors of Treatment Efficacy of AG Chemotherapy. Co-author DOI 10.3389/fonc.2022.844527↗
  13. Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiot… Co-author DOI 10.3389/fonc.2022.879661↗
  14. Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.898119↗
  15. Zinc finger protein 91 accelerates tumour progression by activating β-catenin signalling in pancreatic cancer. Co-author DOI 10.1111/cpr.13031↗
  16. Ligand-targeted polymerase chain reaction for the detection of folate receptor-positive circulating tumour cells as a potential diagnostic biomarker for pancre… Co-author DOI 10.1111/cpr.12880↗
  17. Mind Bomb 1 Promotes Pancreatic Cancer Proliferation by Activating β-Catenin Signaling. Last author DOI 10.1166/jnn.2020.18755↗
  18. The efficacy of combination of induction chemotherapy and irreversible electroporation ablation for patients with locally advanced pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.25110↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hao Cheng · 8 shared papers, 2020–2025 · strength 1.37
  2. Zhenghua Cai · 3 shared papers, 2024–2026 · strength 0.75
  3. Neng Tang · 4 shared papers, 2020–2025 · strength 0.70
  4. Hexing Hang · 3 shared papers, 2024–2025 · strength 0.65
  5. Linxi Zhu · 4 shared papers, 2022–2025 · strength 0.64
  6. Qi Li · 4 shared papers, 2022–2025 · strength 0.56
  7. Baorui Liu · 4 shared papers, 2022 · strength 0.52
  8. Elyar Abaydulla · 2 shared papers, 2025–2026 · strength 0.51
  9. Xiao Fu · 3 shared papers, 2020–2025 · strength 0.49
  10. Juan Du · 3 shared papers, 2022–2025 · strength 0.48
  11. Song Zhang · 2 shared papers, 2025 · strength 0.40
  12. Shanshan Shen · 2 shared papers, 2025 · strength 0.40
  13. Jian He · 3 shared papers, 2020–2022 · strength 0.39
  14. Changchang Lu · 3 shared papers, 2022 · strength 0.37
  15. Lei Wang · 3 shared papers, 2022 · strength 0.37
  16. Xin Qiu · 3 shared papers, 2022 · strength 0.37
  17. Huizi Sha · 2 shared papers, 2022–2025 · strength 0.35
  18. Liang Chen · 1 shared paper, 2024 · strength 0.31
  19. Hong Zang · 1 shared paper, 2024 · strength 0.31
  20. Jie Chen · 1 shared paper, 2026 · strength 0.30
  21. Yu Xie · 1 shared paper, 2025 · strength 0.27
  22. Wei He · 2 shared papers, 2020–2022 · strength 0.26
  23. Hao Cheng · 1 shared paper, 2024 · strength 0.26
  24. Juan Du · 2 shared papers, 2022 · strength 0.25
  25. Jun Chen · 2 shared papers, 2022 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.